BACKGROUND: Limited evidence exists on the prognostic role of continuing medical therapy in patients with heart failure (HF) ...

Patients who have been treated for heart failure and experience an improvement in their pump function are still at higher ...

Inter-atrial shunt device therapy has shown mixed results in clinical trials, with clinical 'non-responders' typically showing features of more advanced heart failure. We aimed to analyse the ...

China: A recent study highlights the potential risks associated with sarcopenic obesity (SO) in diabetic patients with heart ...

BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment ...

Bayer has won U.S. Food and Drug Administration priority review for its application seeking expanded approval of its kidney-disease drug Kerendia in certain people with heart failure.

Out-of-hospital cardiac arrest (OHCA) in people experiencing a heart attack is a time-dependent medical emergency requiring ...

Patients who have been treated for heart failure and experience an improvement of their pump function, are still at higher risk of heart-related death or hospitalization if they stop taking heart ...

Medera is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics. Medera operates via ...

Berlin: Bayer has announced that the Company has received Priority Review designation from the U.S. Food and Drug ...

Patients who have been treated for heart failure and experience an improvement of their pump function, are still at higher risk of heart-related death ...